A day after closing Merck’s $41 billion takeover of Schering-Plough, Merck CEO
Dick Clark showed that his appetite for deal-making hasn’t been sated.
Clark told us today that the newly combined company is “actively looking” for biotechs to buy or ...
[Published Nov 04 2009 by WSJ.com: Health Blog]